Scrip
16 November 2009
Asher Mullard
Merck & Co's Zetia (ezetimibe) has suffered a further blow after it was shown to be less effective than
Abbott's extended-release niacin product Niaspan in the prematurely terminated ARBITER 6 HALTS trial. The results are "not that surprising", according to some cardiologists, but more...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US benefits fund sues Merck & Co and Schering-Plough over Vytorin costs
- Merck & Co and Schering-Plough settle with US states on Vytorin marketing probe
- Crestor's AURORA dims in dialysis patients
- ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
